Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Sold by Bailard Inc.

Bailard Inc. trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,417 shares of the medical research company’s stock after selling 23 shares during the period. Bailard Inc.’s holdings in Thermo Fisher Scientific were worth $3,406,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Vanguard Group Inc. increased its stake in Thermo Fisher Scientific by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 32,760,738 shares of the medical research company’s stock valued at $16,582,503,000 after buying an additional 180,618 shares during the period. Morgan Stanley boosted its position in shares of Thermo Fisher Scientific by 0.4% during the 3rd quarter. Morgan Stanley now owns 12,418,429 shares of the medical research company’s stock valued at $6,285,838,000 after purchasing an additional 50,736 shares in the last quarter. Northern Trust Corp boosted its position in shares of Thermo Fisher Scientific by 2.6% during the 3rd quarter. Northern Trust Corp now owns 3,929,225 shares of the medical research company’s stock valued at $1,988,856,000 after purchasing an additional 99,377 shares in the last quarter. Wellington Management Group LLP boosted its holdings in shares of Thermo Fisher Scientific by 9.8% in the third quarter. Wellington Management Group LLP now owns 3,080,687 shares of the medical research company’s stock worth $1,559,351,000 after buying an additional 274,464 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its holdings in Thermo Fisher Scientific by 0.4% during the third quarter. Charles Schwab Investment Management Inc. now owns 2,184,928 shares of the medical research company’s stock valued at $1,105,945,000 after purchasing an additional 8,672 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. HSBC increased their price target on Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Evercore ISI raised their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a research note on Thursday, April 4th. Barclays raised their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the company an “equal weight” rating in a research note on Thursday. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $606.76.

Insider Activity at Thermo Fisher Scientific

In related news, Director Debora L. Spar sold 164 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Thermo Fisher Scientific news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,039,491.68. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 0.7 %

Shares of NYSE:TMO traded down $4.01 during trading on Thursday, hitting $573.38. 789,741 shares of the company were exchanged, compared to its average volume of 1,558,063. The firm has a fifty day moving average price of $572.61 and a two-hundred day moving average price of $529.06. The stock has a market cap of $218.86 billion, a price-to-earnings ratio of 36.99, a P/E/G ratio of 2.42 and a beta of 0.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The company has a current ratio of 1.75, a quick ratio of 1.39 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.